The owner and founder of the company - a trained physician from the prestigious university of Heidelberg in Germany - has more than 25 years experience in academia and industry including MNC and Nasdaq listed companies where she most recently over the past 4 years served as Chief Medical Officer in the area of Cell and Gene therapy for US and a China based company. Her impressive track record includes multiple IND filings including CAR-T and successfully establishing collaborations with large cooperations including establishing manufacturing collaborations.

She is well aversed with proven track record in finding solutions to complex questions in the area of drug development, regulatory pathways, development hurdles including clinical and manufacturing as well as Due Diligence and rounds of financing. Most recently she actively participated in C round and a successful IPO on Nasdaq for a China based Cell and Gene therapy company as well a due diligence activities.

Her expertise spans from simple drug development clincial trial strategy including Investigator Initiated Studies (IIT) questions to more complex topics of strategic importance including regulatory filings and novel indications in areas of rare disease as well as hematological malignancies and solid tumors.